2017 Q2 Form 10-Q Financial Statement
#000119312517163872 Filed on May 09, 2017
Income Statement
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| Revenue | $305.0K | $305.0K | $305.0K |
| YoY Change | 0.0% | 0.0% | |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $4.290M | $3.930M | $4.270M |
| YoY Change | 52.67% | -7.96% | 57.56% |
| % of Gross Profit | |||
| Research & Development | $9.862M | $9.552M | $4.786M |
| YoY Change | 60.85% | 99.58% | 177.77% |
| % of Gross Profit | |||
| Depreciation & Amortization | $70.00K | $10.00K | $50.00K |
| YoY Change | 600.0% | -80.0% | -44.44% |
| % of Gross Profit | |||
| Operating Expenses | $14.15M | $13.48M | $9.058M |
| YoY Change | 58.26% | 48.84% | 104.29% |
| Operating Profit | -$13.84M | -$13.18M | -$8.753M |
| YoY Change | 60.32% | 50.54% | 97.41% |
| Interest Expense | $290.0K | $259.0K | $144.0K |
| YoY Change | 5.07% | 79.86% | -142.48% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $203.0K | $206.0K | -$1.577M |
| YoY Change | -26.45% | -113.06% | 230.61% |
| Pretax Income | -$13.64M | -$12.97M | -$10.33M |
| YoY Change | 63.16% | 25.56% | 110.39% |
| Income Tax | $0.00 | $0.00 | |
| % Of Pretax Income | |||
| Net Earnings | -$13.64M | -$12.97M | -$10.33M |
| YoY Change | 63.18% | 25.57% | 110.34% |
| Net Earnings / Revenue | -4471.8% | -4252.79% | -3386.89% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$699.5K | -$711.5K | -$581.0K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 18.26M shares | 18.24M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $132.0M | $95.20M | $134.3M |
| YoY Change | 4.85% | -29.11% | |
| Cash & Equivalents | $22.99M | $22.36M | $23.19M |
| Short-Term Investments | $109.0M | $72.80M | $111.1M |
| Other Short-Term Assets | $1.800M | $1.600M | $1.100M |
| YoY Change | 50.0% | 45.45% | |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $134.2M | $97.06M | $135.8M |
| YoY Change | 5.33% | -28.51% | |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $260.0K | $234.0K | $275.0K |
| YoY Change | -14.47% | -14.91% | |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $239.0K | $376.0K | $217.0K |
| YoY Change | 38.15% | 73.27% | |
| Total Long-Term Assets | $499.0K | $610.0K | $492.0K |
| YoY Change | 4.61% | 23.98% | |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $134.2M | $97.06M | $135.8M |
| Total Long-Term Assets | $499.0K | $610.0K | $492.0K |
| Total Assets | $134.7M | $97.67M | $136.3M |
| YoY Change | 5.33% | -28.32% | |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $3.362M | $2.741M | $2.225M |
| YoY Change | 111.71% | 23.19% | |
| Accrued Expenses | $6.900M | $7.000M | $3.600M |
| YoY Change | 86.49% | 94.44% | |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $11.51M | $10.99M | $7.035M |
| YoY Change | 75.57% | 56.2% | |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $214.0K | $148.0K | $243.0K |
| YoY Change | -7.76% | -39.09% | |
| Total Long-Term Liabilities | $13.82M | $14.06M | $15.38M |
| YoY Change | -8.22% | -8.55% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $11.51M | $10.99M | $7.035M |
| Total Long-Term Liabilities | $13.82M | $14.06M | $15.38M |
| Total Liabilities | $25.33M | $25.05M | $22.41M |
| YoY Change | 17.18% | 11.77% | |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$331.9M | -$318.3M | -$271.2M |
| YoY Change | 18.75% | 17.38% | |
| Common Stock | $441.2M | $390.9M | $384.8M |
| YoY Change | 14.44% | 1.59% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $109.3M | $72.62M | $113.8M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $134.7M | $97.67M | $136.3M |
| YoY Change | 5.33% | -28.32% |
Cashflow Statement
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$13.64M | -$12.97M | -$10.33M |
| YoY Change | 63.18% | 25.57% | 110.34% |
| Depreciation, Depletion And Amortization | $70.00K | $10.00K | $50.00K |
| YoY Change | 600.0% | -80.0% | -44.44% |
| Cash From Operating Activities | -$11.80M | -$12.67M | -$6.400M |
| YoY Change | 71.26% | 97.97% | -129.13% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $0.00 | $133.0K |
| YoY Change | -100.0% | -100.0% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$36.60M | $11.06M | -$47.00M |
| YoY Change | 6435.71% | -123.53% | 100.26% |
| Cash From Investing Activities | -$36.60M | $11.06M | -$47.14M |
| YoY Change | 5803.23% | -123.46% | 100.85% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 48.98M | 120.0K | 53.55M |
| YoY Change | -4082.11% | -99.78% | -7642.25% |
| NET CHANGE | |||
| Cash From Operating Activities | -11.80M | -12.67M | -6.400M |
| Cash From Investing Activities | -36.60M | 11.06M | -47.14M |
| Cash From Financing Activities | 48.98M | 120.0K | 53.55M |
| Net Change In Cash | 580.0K | -1.537M | 10.00K |
| YoY Change | -106.64% | -15470.0% | -100.45% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$11.80M | -$12.67M | -$6.400M |
| Capital Expenditures | $0.00 | $0.00 | $133.0K |
| Free Cash Flow | -$11.80M | -$12.67M | -$6.533M |
| YoY Change | 73.27% | 93.94% | -129.74% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
18255943 | shares |
| CY2016Q1 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
0 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
23187000 | |
| CY2017Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18244917 | shares |
| CY2017Q1 | us-gaap |
Assets
Assets
|
97667000 | |
| CY2017Q1 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
100000 | |
| CY2017Q1 | us-gaap |
Assets Current
AssetsCurrent
|
97057000 | |
| CY2017Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
21000 | |
| CY2017Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
23000 | |
| CY2017Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
70429000 | |
| CY2017Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
390894000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
22356000 | |
| CY2017Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2017Q1 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
13915000 | |
| CY2017Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
70431000 | |
| CY2017Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2741000 | |
| CY2017Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1220000 | |
| CY2017Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-2000 | |
| CY2017Q1 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
2419000 | |
| CY2017Q1 | us-gaap |
Supplies
Supplies
|
310000 | |
| CY2017Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-318279000 | |
| CY2017Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4170000 | |
| CY2017Q1 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
102000 | |
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18215181 | shares |
| CY2016Q4 | us-gaap |
Assets
Assets
|
109013000 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
108510000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
67000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
11000 | |
| CY2017Q1 | sndx |
Reimbursable Costs
ReimbursableCosts
|
374000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
23179000 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q1 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
7028000 | |
| CY2017Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q1 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
220000 | |
| CY2017Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2017Q1 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
210000 | |
| CY2017Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
637000 | |
| CY2017Q1 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
14063000 | |
| CY2017Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2017Q1 | us-gaap |
Liabilities
Liabilities
|
25052000 | |
| CY2017Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
97667000 | |
| CY2017Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
148000 | |
| CY2017Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10989000 | |
| CY2017Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
376000 | |
| CY2017Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
234000 | |
| CY2017Q1 | us-gaap |
Short Term Investments
ShortTermInvestments
|
70429000 | |
| CY2017Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
72615000 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2016Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
81486000 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
389374000 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
23844000 | |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
14220000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
81430000 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2375000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1220000 | |
| CY2016Q4 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
1630000 | |
| CY2016Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
56000 | |
| CY2016Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
6771000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q1 | us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
6000 | |
| CY2017Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-03-31 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1488000 | |
| CY2016Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
202000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2016Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
306000 | |
| CY2016Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
168000 | |
| CY2016Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
14508000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
24874000 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
109013000 | |
| CY2016Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
288000 | |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10366000 | |
| CY2016Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
243000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
260000 | |
| CY2016Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
81486000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
84139000 | |
| CY2016Q4 | us-gaap |
Supplies
Supplies
|
461000 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-305293000 | |
| CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3029000 | |
| CY2016Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
151000 | |
| CY2016Q4 | sndx |
Reimbursable Costs
ReimbursableCosts
|
262000 | |
| CY2017Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
SYNDAX PHARMACEUTICALS INC | |
| CY2017Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2017Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001395937 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.71 | |
| CY2017Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1377000 | |
| CY2017Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
259000 | |
| CY2017Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
305000 | |
| CY2017Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
206000 | |
| CY2017Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-53000 | |
| CY2017Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | |
| CY2017Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2017Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2017Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3930000 | |
| CY2017Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-13029000 | |
| CY2017Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2017Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
25095000 | |
| CY2017Q1 | us-gaap |
Licenses Revenue
LicensesRevenue
|
305000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-7000 | |
| CY2017Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
13482000 | |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12971000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
11063000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
366000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1141000 | |
| CY2017Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-12971000 | |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13177000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
117000 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-58000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
14081000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-305000 | |
| CY2017Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2017Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <b>1. Nature of Business</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Syndax Pharmaceuticals, Inc. (the Company) is a clinical stage biopharmaceutical company developing an innovative pipeline of combination therapies in multiple cancer indications. The Company’s lead product candidate, entinostat, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Entinostat was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from the Company’s Phase 2b clinical trial, ENCORE 301. The Company is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, a monoclonal antibody that targets the colony stimulating <font style="WHITE-SPACE: nowrap">factor-1</font> receptor to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Given its potential ability to block the function of immune suppressive cells in the tumor microenvironment, the Company is evaluating entinostat as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for <font style="WHITE-SPACE: nowrap">non-small</font> cell lung cancer and melanoma; with Genentech, Inc. for triple negative breast cancer; and with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. for ovarian cancer. The Company is evaluating SNDX-6352 in a single ascending dose Phase 1 clinical trial. In April 2017, a fourth cohort for microsatellite stable colorectal cancer was added to the Phase 1b/2 clinical trial with Merck & Co., Inc. The Company plans to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional cancer therapies to expand our pipeline.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> In March 2016, the Company completed its initial public offering (“IPO”) whereby it sold 4,809,475 shares of common stock at the initial public offering price of $12.00 per share, which included 409,475 shares issued pursuant to the underwriters’ partial exercise of their over-allotment option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were $50.5 million, net of underwriting discounts and commissions of $4.0 million and offering expenses of $3.1 million. Upon the closing of the IPO, all outstanding shares of the Company’s outstanding convertible preferred stock converted into 12,872,551 shares of common stock; and the Company’s outstanding warrant liability to purchase 357,840 shares of the Company’s common stock valued at $4.6 million was reclassified to additional <font style="WHITE-SPACE: nowrap">paid-in</font> capital. In connection with the closing of the Company’s IPO, the Company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, both of which were approved by the Company’s board of directors and stockholders on September 28, 2015 and February 24, 2016, respectively. Pursuant to the amended and restated certificate of incorporation, the Company is now authorized to issue 100,000,000 shares of common stock and 10,000,000 shares of preferred stock.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks common to companies in the development stage, including, but not limited to, successful development of therapeutics, obtaining additional funding, protection of proprietary therapeutics, compliance with government regulations, fluctuations in operating results, dependence on key personnel and collaborative partners, and risks associated with industry changes. The Company’s long-term success is dependent upon its ability to successfully develop and market its product candidates, expand its oncology drug pipeline, earn revenue, obtain additional capital when needed, and ultimately, achieve profitable operations. The Company anticipates that it will be several years before either entinostat or SNDX-6352 is approved, if ever, and the Company begins to generate revenue from sales of entinostat and SNDX-6352. Accordingly, management expects to incur substantial losses on the ongoing development of entinostat and SNDX-6352 and does not expect to achieve positive cash flow from operations for the foreseeable future, if ever. As a result, the Company will continue to require additional capital to move forward with its business plan. While certain amounts of this additional capital were raised in the past, there can be no assurance that funds necessary beyond these amounts will be available in amounts or on terms sufficient to ensure ongoing operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company’s management believes that the cash, cash equivalents and short-term investments balances as of March 31, 2017 should enable the Company to maintain its planned operations for at least the next 12 months. The Company’s ability to fund all of its planned operations internally beyond that date, including the completion of its ongoing and planned clinical trial activities, may be substantially dependent upon whether the Company can obtain sufficient funding on terms acceptable to the Company. Proceeds from additional capital transactions would allow the Company to accelerate and/or expand its planned research and development activities. In the event that sufficient funds were not available, the Company may be required to delay or reduce expenditures to conserve cash, which could involve scaling back or curtailing development and general and administrative activities.</p> </div> | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-12668000 | |
| CY2017Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-7000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-49000 | |
| CY2017Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
28200 | shares |
| CY2017Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions.</p> </div> | |
| CY2017Q1 | dei |
Trading Symbol
TradingSymbol
|
SNDX | |
| CY2017Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9552000 | |
| CY2017Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
118000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
200000 | |
| CY2017Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-1000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1377000 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
18231602 | shares |
| CY2017Q1 | sndx |
Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
|
11000 | |
| CY2017Q1 | sndx |
Issuance Costs Included In Accounts Payable And Accrued Expenses
IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
|
135000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
8000 | |
| CY2016Q1 | us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
53000 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.85 | |
| CY2016Q1 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
328942000 | |
| CY2016Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2190000 | |
| CY2016Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
73000 | |
| CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4272000 | |
| CY2016Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-10130000 | |
| CY2016Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1703000 | |
| CY2016Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
144000 | |
| CY2016Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
305000 | |
| CY2016Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1577000 | |
| CY2016Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-18000 | |
| CY2016Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
31857000 | |
| CY2016Q1 | us-gaap |
Licenses Revenue
LicensesRevenue
|
305000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
1285000 | |
| CY2016Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
9058000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10330000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-47137000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-403000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
613000 | |
| CY2016Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-12928000 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8753000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
53548000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
200000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
78863000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-305000 | |
| CY2016Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6403000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
133000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-2000 | |
| CY2016Q1 | us-gaap |
Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
|
2598000 | |
| CY2016Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
53549000 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4786000 | |
| CY2016Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-1000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2190000 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
4541536 | shares |
| CY2016Q1 | sndx |
Fair Value Adjustment Of Warrants And Derivative Liabilities
FairValueAdjustmentOfWarrantsAndDerivativeLiabilities
|
-1720000 | |
| CY2016Q1 | sndx |
Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
|
10000 | |
| CY2016Q1 | sndx |
Reclassification Of Common Stock Warrant Liability To Additional Paid In Capital
ReclassificationOfCommonStockWarrantLiabilityToAdditionalPaidInCapital
|
4551000 | |
| CY2016Q1 | sndx |
Issuance Costs Included In Accounts Payable And Accrued Expenses
IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
|
1400000 |
